OBR Daily Commentary

forumImage

Fact Checking the NYT Fact Check on the Trump Proposal

(MSK Drug Pricing Lab) Dec 17, 2018 - The Drug Pricing Lab takes issue with The New York Times ‘Fact Check’ on the recent Trump Administration proposal to pilot alternative reimbursement for Part B drugs.

Read Article arrow

Ted Okon (Posted: December 18, 2018)

quotesAs I informed Dr. Bach, at least one of his "fact check" statements are not factual. "...McKesson, which owns Texas Oncology (part of US Oncology)" is not correct because the physicians of Texas Oncology own Texas Oncology. It calls into question what other "fact checks" by Dr. Bach are incorrect.quotes

Add Comment 1 Comment
forumImage

Azar Announces Mandatory Oncology Payment Model Is Coming

(AJMC Managed Markets Network) Nov 8, 2018 - A mandatory payment model is coming in oncology care, HHS Secretary Alex Azar said today during an appearance at a value-based care summit. Azar said that the administration would “revisit” mandatory models that it had previously scrapped in cardiac care and said the time had come for “exploring new and improved episode-based models in other areas, including radiation oncology.” Right now, the Centers for Medicare and Medicaid Innovation is working with practices on care transformation through the Oncology Care Model, or OCM, but that that 5-year pilot is voluntary.

Read Article arrow

Ted Okon (Posted: November 08, 2018)

quotesThis is yet another mandatory experiment on cancer patient care that is terrible medicine and unconstitutional by using the Medicare Innovation Center to bypass the Congress and existing law. The regulators are now running medicine, and that is both scary and dangerous!quotes

Add Comment 1 Comment
forumImage

Study: Community Oncology Practices Have Lost $78 Million Due to Medicare Sequester

(COA) Aug 29, 2018 - Community oncology practices have lost $78 million as a result of the ongoing Medicare sequester cut to reimbursement for Part B drugs. This amounts to practices losing an average of more than $847,000 each due to the sequester cut, which has driven an increase in the number of closings and rate of closure of community oncology practices in the United States. Sequestration is an automatic cut to Federal government spending triggered because Congress was unable to negotiate a balanced budget in 2011. The blunt budget cutting gimmick has been extended multiple times, with the current sequester scheduled to continue through 2027. Beginning in 2013, the Centers for Medicare & Medicaid Services (CMS) began to apply a 2% budget sequester cut to all Medicare Part B reimbursement, including for drugs. The study found that all community oncology practices experienced a significant impact from sequestration. Examining data and reimbursement over a 27-month study period from January 2016 to March 2018, the authors found that at the beginning of 2016, each practice, on average, experienced an approximate 28% to 31% loss due to sequestration. This remained steady for large practices, while the small and medium practices began to experience more impact (38.4% and 34.7%, respectively). The overall average loss was 32% in the first quarter of 2018.

Read Article arrow

Ted Okon (Posted: August 29, 2018)

quotesVery important analysis conducted by Dr. Lucio Gordan and fellow researchers. Shows the adverse impact that the sequester cut has had on community oncology practices. It's staggering to realize how much these practices have lost. The sequester cut applied to Medicare Part B drugs is illegal, which is why COA is suing the federal government.quotes

Add Comment 1 Comment

Meet the Editorial Board

Prostate Cancer
member photo
Tomasz M. Beer, MD, FACP

Professor of Medicine, Division of Hematology/Medical O...

Community Oncology
member photo
Dean Gesme, MD

FACP FACPE FASCO President, Minnesota Oncology...

Breast Cancer
member photo
Debu Tripathy, MD

Professor and Chair, Department of Breast Medical Oncol...

Lung Cancer
member photo
H. Jack West, MD

Medical Director, Thoracic Oncology Program, Swedish Ca...

Gastrointestinal Cancers
member photo
Howard S. Hochster, MD

Distinguished Professor of Medicine, Rutgers Robert Woo...

Radiation Oncology
member photo
Howard Sandler, MD, MS, FASTRO

Ronald H. Bloom Chair in Cancer Therapeutics
Pr...

Community Oncology
member photo
Jeff Patton, M.D.

CEO Tennessee Oncology...

Precision Medicine Section Editor
member photo
Jennifer Levin Carter, MD, MPH

Chief Medical Officer and Founder, N-of-One...

Financial Sector
member photo
Michael G. King Jr.

Managing Director and Senior Biotechnology Analyst...

Gastrointestinal Cancers
member photo
Richard Goldberg, MD

Director WVU Cancer Institute Director of Cancer Signa...

Editor-In-Chief
member photo
Robert A. Figlin, MD., FACP

Professor and Director, Division of Hematology Oncology...

Health Policy
member photo
Ted Okon

Executive Director Community Oncology Alliance...

Community Oncology
member photo
Thomas Marsland, MD

Vice President Integrated Community Oncology Network ...

Community Oncology
member photo
William Harwin MD

Florida Cancer Specialists President and Managing Part...

Health Policy
member photo
William McGivney, PhD

National Health Policy Expert...

Payer
member photo
Winston Wong, PharmD

President, W-Squared Group...